COST-EFFECTIVENESS OF ICOSAPENT ETHYL FOR PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED TRIGLYCERIDES IN GREECE

被引：0
|
作者：
Stratopoulos, A. [1 ]
Kougioumtzoglou, I [2 ]
Mortaki, K. [1 ]
Rigopoulos, P. [1 ]
Jakouloff, D. [3 ]
机构：
[1] Vianex SA, Athens, Greece
[2] Univ West Attica, Athens, Greece
[3] Amarin Switzerland GmbH, Zug, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE9
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF ICOSAPENT ETHYL FOR PREVENTING CARDIOVASCULAR EVENTS
    Dressel, A.
    [J]. ATHEROSCLEROSIS, 2023, 379
  • [2] Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
    Pareek, Manan
    Mason, R. Preston
    Bhatt, Deepak L.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2022, 21 (01) : 31 - 42
  • [3] Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
    Lachaine, Jean
    Charron, Jean -Nicolas
    Gregoire, Jean C.
    Hegele, Robert A.
    Leiter, Lawrence A.
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 295 - 308
  • [4] Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
    Weintraub, William S.
    Bhatt, Deepak L.
    Zhang, Zugui
    Dolman, Sarahfaye
    Boden, William E.
    Bress, Adam P.
    King, Jordan B.
    Bellows, Brandon K.
    Tajeu, Gabriel S.
    Derington, Catherine G.
    Johnson, Jonathan
    Andrade, Katherine
    Steg, P. Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    Kolm, Paul
    [J]. JAMA NETWORK OPEN, 2022, 5 (02) : E2148172
  • [5] ICOSAPENT ETHYL IN ADDITION TO STATINS IS A COST-EFFECTIVE TREATMENT IN PATIENTS AT HIGH CARDIOVASCULAR RISK WITH ELEVATED TRIGLYCERIDES AND ESTABLISHED CARDIOVASCULAR DISEASE OR DIABETES WITH RISK FACTOR IN THE NETHERLANDS
    Pronk, L. M.
    Piena, M.
    Van de Pas, M.
    Jakouloff, D.
    Giesen, E.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S308 - S308
  • [6] Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK
    Michaeli, D. T.
    Michaeli, J. C.
    Boch, T.
    Michaeli, T.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 2845 - 2845
  • [7] COST-EFFECTIVENESS OF ICOSAPENT ETHYL (IPE) FOR THE REDUCTION OF THE RISK OF ISCHEMIC CARDIOVASCULAR EVENTS IN CANADA.
    Lachaine, J.
    Charron, J. N.
    Gregoire, J. C.
    Hegele, R. A.
    Leiter, L. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S496 - S496
  • [8] COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
    Weintraub, William S.
    Bhatt, Deepak
    Zhang, Zugui
    Zhang, Cheng
    Sarahfaye, Dolman
    Boden, William E.
    Steg, Philippe Gabriel
    Miller, Michael
    Brinton, Eliot
    King, Jordan
    Bress, Adam
    Jacobson, Terry
    Tardif, Jean Claude
    Ballantyne, Christie M.
    Kolm, Paul
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1914 - 1914
  • [9] Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT
    Weintraub, William S.
    Bhatt, Deepak L.
    Zhang, Zugui
    Dolman, Sarahfaye F.
    Zhang, Cheng
    Boden, William E., II
    Bress, Adam P.
    King, Jordan B.
    Steg, Philippe G.
    Brinton, Eliot A.
    Jacobson, Terry A.
    Tardif, Jean Claude
    Ballantyne, Christie M.
    Kolm, Paul
    [J]. CIRCULATION, 2019, 140 (25) : E969 - E970
  • [10] The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
    Ademi, Zanfina
    Ofori-Asenso, Richard
    Zomer, Ella
    Owen, Alice
    Liew, Danny
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 897 - 904
12345